NUYOU Privacy Policy

The NUYOU Program has been designed to comply with the Australian Privacy Principles (APPs) and is committed to managing personal information in an open, transparent and secure way.

GlaxoSmithKline Pty Ltd (GSK) has engaged Partizan Worldwide Pty Ltd (Partizan Worldwide) to administer the NUYOU Support Program. In order to provide NUYOU Support Program Services to you, Partizan Worldwide will collect and hold some of your personal information.

To participate in the NUYOU Program, you need to enrol and consent to the NUYOU Support Program Terms and Conditions. In order for the NUYOU Program to provide you with program services, some personal information, such as your name, age, address and telephone number, as well as relevant treatment information will need to be collected.

If you choose not to provide the information requested, it may not be possible for the NUYOU Coordinator to contact you or provide program services as part of the NUYOU Program.

Sensitive personal information will be used by the NUYOU Program Administrators to contact patients and Healthcare Professionals, create an enrolment record; and enter into the NUYOU Program registries, databases and web-based systems hosted in Australia.

Personal sensitive information provided may be disclosed by Partizan Worldwide to the patient’s nominated Healthcare Practitioner(s) or to third party individuals or organisations contracted or involved in the administration of the NUYOU Program located within Australia such as:

  • The patient’s nominated GP/Specialist clinic
  • Government authorities and bodies as required by law

Should you experience an adverse event or product complaint, we will need to provide this to GSK, who may be required to report this, even if it has already been reported by you directly to a doctor, or the regulatory authorities.

As a sponsor, GSK has a responsibility to monitor the use of their products continually and record the safety of the medicine and the balance of its benefit and risk. GSK may disclose your de-identified personal or sensitive information to the relevant regulatory authorities solely for the purpose of, and to the extent required to, report such adverse event.

GSK, or a third party acting on their behalf, may contact a patient’s Healthcare Professional in order to collect further information related to an adverse event. Your de-identified personal information may be processed by GSK, its affiliated companies and GSK’s trusted third party suppliers outside Australia. GSK implement appropriate measures to ensure that your de-identified personal information remains protected and secure when it is transferred outside Australia, in accordance with applicable data protection and privacy laws.

De-identified information relating to a patient’s participation in the NUYOU Program may also be collated into a report for GSK. GSK may use this information to:

  • Develop, evaluate and improve the NUYOU Program, services and materials
  • Enable research, including future scientific research and publications to inform the healthcare community and help future patients

GSK may also share de-identified information with its parent Company or its affiliates regarding how the Programs are working on an aggregated basis. This information does not identify patients individually. Any personal information collected by GSK will be handled in accordance with GSK’s privacy policy available at https://privacy.gsk.com/en-au/privacy-notice/general.

Partizan Worldwide (or third party individuals or organisations contracted or involved in the administration of the NUYOU Program) will retain the sensitive personal information collected for the period of your participation in the NUYOU Program and after your participation in the Program has ended for the purposes of reporting, audit and as required by law. Retention of sensitive personal information is also regulated by medical legislation. Any sensitive personal information relating to adverse event reporting must be retained for seven years after the finalisation of product commercialisation, discontinuation of development, out licensing or other action whereby GSK have no further requirement for monitoring safety of the product.

At your request, Partizan Worldwide (or third party individuals or organisations contracted or involved in the administration of the NUYOU Program) will update your personal information as it changes during the course of your participation in the NUYOU Program.

Please contact the Privacy officer at Partizan Worldwide, Level 8/321 Kent Street, Sydney NSW 2000:

  • if you wish to access the data Partizan Worldwide or third party individuals or organisations contracted or involved in the administration of the NUYOU program hold about you;
  • to make a complaint about the management of your personal or health information or any breach of an APP by Partizan Worldwide or a third party individual or organisation contracted or involved in the administration of the NUYOU program;
  • to withdraw any information currently held by the NUYOU Program
  • if you have comments or questions about this Privacy Policy

If you have any questions about your condition or treatment, please contact your treating healthcare professional.

If you have any questions about the NUYOU Program, please call the program coordinator on 1800 168 968, Monday to Friday 9am - 5pm (AEST).

For more information consult with your healthcare professional.

Approval code NX-AU-MPL-PSP-220004. Date of approval: June 2025.